CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year.

马萨诸塞州剑桥市。-（商业新闻短讯）--Sarepta Therapeutics，Inc.（纳斯达克：SRPT）是罕见疾病精确遗传医学的领导者，今天宣布，被《时代》杂志命名为著名神经肌肉研究员、医生和基因治疗先驱杰瑞·R·门德尔（JerryR.Mendell）的医学博士将参加2024年《时代100健康》（TIME100 Health）的首届会议，该名单列出了今年对全球健康影响最大的100个人。

Dr. Mendell was recognized for his lifetime commitment to neuromuscular disease and achievements in genetic medicine that propelled a new age of treatment for several genetic diseases, including Duchenne muscular dystrophy..

门德尔博士一生致力于神经肌肉疾病，并在遗传医学方面取得了成就，推动了包括杜兴氏肌营养不良症在内的多种遗传疾病的治疗进入了一个新时代。。

The TIME100 Health list recognizes the impact, innovation, and achievement of the world’s most influential individuals in health. TIME selected a community of leaders across industries dedicated to creating tangible and credible change for a healthier population, including pioneering scientists who are steering the evolution of global health in 2024..

《时代100健康榜》表彰了世界上最具影响力的健康人士的影响力、创新和成就。《时代》杂志选择了一个由各行各业的领导者组成的社区，致力于为更健康的人群创造切实可信的变化，其中包括2024年引领全球健康发展的先驱科学家。。

“Dr. Mendell’s humility and compassion for patients and families shines through his relentless focus on advancing science with the potential to change the course of devastating, fatal and once untreatable neuromuscular diseases,” said Louise Rodino-Klapac, Ph.D., executive vice president, head of R&D and chief scientific officer, Sarepta Therapeutics.

Sarepta Therapeutics执行副总裁、研发负责人兼首席科学官Louise Rodino Klapac博士说：“门德尔博士对患者和家属的谦逊和同情，体现在他坚持不懈地致力于推进科学，有可能改变毁灭性、致命性和一度无法治愈的神经肌肉疾病的进程。”。

“I have had the honor of working with Dr. Mendell for many years, first at Nationwide Children’s Hospital and now at Sarepta, to see some of his life’s work come to fruition. Dr. Mendell’s accomplishments in the field of neuromuscular disease, and the care that he provided to patients and their families in more than 50 years of practice, continue to inspire Sarepta and others working to advance the science of genetic medicine.”.

“我有幸与门德尔博士合作多年，先是在全国儿童医院，现在在萨雷普塔，看到他一生的一些工作取得了成果。门德尔博士在神经肌肉疾病领域的成就，以及他在50多年的实践中为患者及其家属提供的护理，继续激励着萨雷普塔和其他致力于推进遗传医学科学的人。”。

Dr. Mendell began his career at the U.S. National Institutes of Health, and shortly after he met his first patient living with Duchenne. His early work was followed by decades as a clinician and researcher at Nationwide Children’s Hospital to understand Duchenne’s progressive muscle wasting trajectory and ways to intervene to slow or alter the course of the disease.

门德尔博士在美国国立卫生研究院（National Institutes of Health）开始了他的职业生涯，不久后他遇到了第一位与杜兴（Duchenne）住在一起的病人。在他早期的工作之后，他在全国儿童医院担任了数十年的临床医生和研究人员，以了解杜兴氏进行性肌肉消瘦的轨迹以及干预减缓或改变疾病进程的方法。

He is a pioneer in gene therapy for neuromuscular diseases, including spinal muscular atrophy (SMA), and during his tenure at Nationwide Children’s served as an investigator for multiple clinical trials, including those for Duchenne and limb-girdle muscular dystrophies (LGMDs). Dr. Mendell recently retired from his clinical and research role at Nationwide Children’s and is now serving as an advisor to Sarepta and to the Center for Gene Therapy in the Abigail Wexner Research Institute at Nationwide Children’s..

他是神经肌肉疾病（包括脊髓性肌萎缩症（SMA））基因治疗的先驱，在Nationwide Children's任职期间，他曾担任多项临床试验的研究者，包括Duchenne和肢带型肌营养不良症（LGMD）的临床试验。门德尔博士最近从Nationwide Children's的临床和研究岗位上退休，目前担任Sarepta和Nationwide Children's Abigail Wexner研究所基因治疗中心的顾问。。

In addition to recognition on the TIME100 Health list, Dr. Mendell is a 2024 recipient of the King Faisal Prize Laureate in Medicine. In 2021, he was elected to the National Academy of Medicine and was the first recipient of the American Society for Gene and Cell Therapy (ASGCT)’s Jerry Mendell Translational Medicine Award.

除了被列入《时代100强健康榜》之外，门德尔博士还是2024年费萨尔国王医学奖得主。2021年，他被选入美国国家医学院，是美国基因与细胞治疗学会（ASGCT）杰里·门德尔转化医学奖的第一位获得者。

He is also a published author of more than 400 peer-reviewed articles and books about skeletal muscle disease, peripheral nerve disorders and gene therapy..

他还发表了400多篇同行评议的文章和书籍，涉及骨骼肌疾病、周围神经疾病和基因治疗。。

About Sarepta Therapeutics

关于Sarepta Therapeutics

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development.

萨雷塔正在执行一项紧急任务：为罕见疾病设计精确的基因医学，这些疾病会破坏生命并缩短未来。我们在杜兴氏肌营养不良症（DMD）和肢带型肌营养不良症（LGMD）方面担任领导职务，目前我们有40多个项目处于不同的发展阶段。

Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on LinkedIn, X (formerly Twitter), Instagram and Facebook..

我们在基因治疗，RNA和基因编辑方面的多平台精密遗传医学引擎推动了我们庞大的管道。有关更多信息，请访问www.sarepta.com或在LinkedIn、X（以前的Twitter）、Instagram和Facebook上关注我们。。

Internet Posting of Information

网上发布信息

We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

我们经常在我们网站www.sarepta.com的“为投资者”部分发布对投资者可能重要的信息。我们鼓励投资者和潜在投资者定期咨询我们的网站，以获取有关我们的重要信息。